Skip to main content
. Author manuscript; available in PMC: 2018 Apr 29.
Published in final edited form as: Nature. 2017 Jul 19;547(7664):413–418. doi: 10.1038/nature23270

Extended Data Figure 6. Analysis of Ptpn2 amplifications in human cancer using exome sequencing.

Extended Data Figure 6

a, Patients treated with anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapies in four cancer types: bladder cancer, head and neck squamous cell carcinoma (HNSCC), lung cancer and melanoma with copy-number amplifications (CNA) of PTPN2 were grouped according to whether or not they received clinical benefit from immunotherapy. The mutational burden is indicated on the y axis and the type of amplification event (focal, arm level or chromosome level) is indicated for each patient.